Fig. 5

A-C: The sensitivity of H128, H128-Mut, H128-BPM or H128-LM cells to carboplatin (A), etoposide (B) and teniposide (C) through the EZH2 degrader. H128 cells were pretreated with PROTAC EZH2 degrader-1 (2 nM) followed by carboplatin (A), etoposide (B) or teniposide (C) treatment for 72 h prior to cell viability assays. D: The viability of cells treated with anlotinib, both alone and in combination with the EZH2i regimen, was examined. E-H: Cell viability was measured 72 h after treatment with PROTAC EZH2 degrader-1 alone (E) or in combination with three regimens (F: carboplatin + etoposide, G: VM26, H: anlotinib)